[{"notes_id":"1_245","category":"1","subcategory":"1","title":"Chronic heart failure: drug management","body":"NICE issued updated guidelines on management in 2018, key points are summarised here.<br \/><br \/>Whilst loop diuretics play an important role in managing fluid overload it should be remembered that no long-term reduction in mortality has been demonstrated for <span class=\"concept\" data-cid=\"4533\">loop diuretics<\/span> such as furosemide.<br \/><br \/><h5 class='notes-heading'>First-line therapy<\/h5><br \/>The first-line treatment for all patients is both an <span class=\"concept\" data-cid=\"1608\"><b>ACE-inhibitor<\/b> and a <b>beta-blocker<\/b><\/span><br \/><ul><li>generally, <span class=\"concept\" data-cid=\"8883\">one drug should be started at a time<\/span>. NICE advise that clinical judgement is used when determining which one to start first<\/li><li>beta-blockers licensed to treat heart failure in the UK include <span class=\"concept\" data-cid=\"9704\">bisoprolol, carvedilol, and nebivolol<\/span>.<\/li><li>ACE-inhibitors and beta-blockers have no effect on mortality in heart failure with <span class=\"concept\" data-cid=\"8881\"><i>preserved<\/i><\/span> ejection fraction <\/li><\/ul><br \/><h5 class='notes-heading'>Second-line therapy<\/h5><br \/>The standard second-line treatment is an <span class=\"concept\" data-cid=\"9528\"><b>aldosterone antagonist<\/b><\/span><br \/><ul><li>these are sometimes referred to as mineralocorticoid receptor antagonists. Examples include spironolactone and eplerenone<\/li><li>it should be remembered that both ACE inhibitors (which the patient is likely to already be on) and aldosterone antagonists both cause hyperkalaemia - therefore potassium should be monitored <\/li><\/ul><br \/>There is an increasing role for <span class=\"concept\" data-cid=\"11988\"><b>SGLT-2 inhibitors<\/b><\/span> in the management of heart failure with a reduced ejection fraction<br \/><ul><li>these drugs reduce glucose reabsorption and increase urinary glucose excretion<\/li><li>examples include canagliflozin, dapagliflozin and empagliflozin<\/li><li>the evidence base shows  SGLT-2 inhibitors reduced hospitalisation secondary to heart failure and cardiovascular death<\/li><li>international guidelines widely recommend their usage. In terms of NICE, a technology appraisal from 2021 support the use of dapagliflozin as an add-on to optimised standard care<\/li><\/ul><br \/><h5 class='notes-heading'>Third-line therapy<\/h5><br \/>Third-line treatment should be initiated by a specialist. Options include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin and cardiac resynchronisation therapy<br \/><ul><li>ivabradine<ul><li>criteria: <span class=\"concept\" data-cid=\"10964\">sinus rhythm > 75\/min and a left ventricular fraction < 35%<\/span><\/li><\/ul><\/li><li><span class=\"concept\" data-cid=\"2407\">sacubitril-valsartan<\/span><ul><li>criteria: left ventricular fraction < 35%<\/li><li>is considered in heart failure with reduced ejection fraction who are symptomatic on ACE inhibitors or ARBs<\/li><li><span class=\"concept\" data-cid=\"9700\">should be initiated following ACEi or ARB wash-out period<\/span><\/li><\/ul><\/li><li>digoxin<ul><li>digoxin has also not been proven to reduce mortality in patients with heart failure. It may however improve symptoms due to its inotropic properties<\/li><li>it is strongly indicated if there is coexistent <span class=\"concept\" data-cid=\"2862\">atrial fibrillation<\/span><\/li><\/ul><\/li><li>hydralazine in combination with nitrate<ul><li>this may be particularly indicated in <span class=\"concept\" data-cid=\"3665\">Afro-Caribbean patients<\/span><\/li><\/ul><\/li><li>cardiac resynchronisation therapy<ul><li>indications include a <span class=\"concept\" data-cid=\"10963\">widened QRS (e.g. left bundle branch block) complex on ECG<\/span><\/li><\/ul><\/li><\/ul><br \/>Other treatments<br \/><ul><li>offer <span class=\"concept\" data-cid=\"9705\"><b>annual influenza vaccine<\/b><\/span><\/li><li>offer one-off <b>pneumococcal vaccine<\/b><ul><li>adults usually require just one dose but those with asplenia, splenic dysfunction or chronic kidney disease need a booster every 5 years<\/li><\/ul><\/li><\/ul><br \/><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd975b.png\" data-fancybox=\"gallery\" data-caption=\"\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https:\/\/d32xxyeh8kfs8k.cloudfront.net\/images_Passmedicine\/pdd975.png\" alt=\"\" \/><\/a><\/div><\/div><\/div>","notes_hash":"ef7b09917f0a69047baab0b3496da189","knowledge_graph_node_id_link":1072,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_265\" data-linkid=\"265\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_265\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">16<\/span><button type=\"button\" style=\"\" id=\"link_dislike_265\" data-linkid=\"265\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_265\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">18<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ta267\/chapter\/1-Guidance\">2012 Guidance on ivabradine<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1065\" data-linkid=\"1065\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1065\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">36<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1065\" data-linkid=\"1065\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1065\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">23<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng106\/chapter\/Recommendations\">2018 Chronic heart failure guidelines<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/q2t9sFITAIY\" data-description=\"Chronic Heart Failure: Visual Explanation for Students\" data-upvotes=\"23\" data-downvotes=\"0\" data-media=\"775\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/q2t9sFITAIY\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/q2t9sFITAIY\" data-description=\"Chronic Heart Failure: Visual Explanation for Students\" data-upvotes=\"23\" data-downvotes=\"0\" data-media=\"775\">Chronic Heart Failure: Visual Explanation for Students<\/a><\/td><\/tr><tr><td><span ><small>Zero To Finals - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1347\" data-mediaid=\"1347\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1347\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">23<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1347\" data-mediaid=\"1347\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1347\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/ifxS8JMJR6k\" data-description=\"Heart failure\" data-upvotes=\"4\" data-downvotes=\"3\" data-media=\"914\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/ifxS8JMJR6k\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/ifxS8JMJR6k\" data-description=\"Heart failure\" data-upvotes=\"4\" data-downvotes=\"3\" data-media=\"914\">Heart failure<\/a><\/td><\/tr><tr><td><span ><small>Osmosis - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1586\" data-mediaid=\"1586\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_1586\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">4<\/span><button type=\"button\" style=\"\" id=\"media_dislike_1586\" data-mediaid=\"1586\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_1586\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">3<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/ItKGeEbzAis\" data-description=\"Heart failure with reduced and preserved ejection fraction\" data-upvotes=\"6\" data-downvotes=\"6\" data-media=\"1467\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/ItKGeEbzAis\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/ItKGeEbzAis\" data-description=\"Heart failure with reduced and preserved ejection fraction\" data-upvotes=\"6\" data-downvotes=\"6\" data-media=\"1467\">Heart failure with reduced and preserved ejection fraction<\/a><\/td><\/tr><tr><td><span ><small>Armando Hasudungan - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2582\" data-mediaid=\"2582\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_2582\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">6<\/span><button type=\"button\" style=\"\" id=\"media_dislike_2582\" data-mediaid=\"2582\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_2582\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">6<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"1608":{"concept_text":"Patients with heart failure with reduced LVEF should be given a beta blocker and an ACE inhibitor as first-line treatment","concept_percentile":"78"},"2862":{"concept_text":"Digoxin is strongly indicated if there is co-existent atrial fibrillation with chronic heart failure","concept_percentile":"89"},"9528":{"concept_text":"Offer a mineralcorticoid receptor antagonist, in addition to an ACE inhibitor (or ARB) and beta-blocker, to people who have heart failure with reduced ejection fraction if they continue to have symptoms of heart failure","concept_percentile":"86"},"11988":{"concept_text":"SGLT-2 inhibitors should be considered as second-line therapy in patients with HFrEF in addition to optimised standard care","concept_percentile":"60"}},"category_name":"Cardiovascular","subcategory_name":"Cardiology","comment_count":16},"",[]]